Streamlining Gene Therapy with AAVs: Innovations in Plasmid Design and Vector Production

This white paper, which was sponsored by WuXi AppTec and published by Chemical & Engineering News (C&EN) delves into advancements in adeno-associated virus (AAV)-based gene therapy development. It highlights cutting-edge solutions brought to market by OXGENE, a WuXi Advanced Therapies company including:

1. SnapFast™ Plasmids – A modular plasmid system enabling rapid creation and optimization of expression constructs to streamline gene therapy workflows.
2. TESSA® Technology – A novel adenovirus-enabled system for safer, more efficient AAV production, achieving higher yields, improved safety, and scalability for clinical-grade manufacturing.

These innovations address key challenges in gene therapy, including optimizing expression, enhancing viral titers, and reducing contamination risks, ultimately accelerating the path to life-changing therapies.